Twist Bioscience agrees to governance reforms in proposed shareholder lawsuit settlement

• Twist Bioscience reached a proposed settlement of shareholder derivative litigation under an agreement dated October 15, 2026, subject to court approval.
• The Delaware federal court will consider final approval and dismissal with prejudice at a January 22, 2027, hearing.
• The proposed settlement requires the board to adopt corporate governance reforms within 45 days of final court approval.
• Individual defendants' insurers would pay $1 million in attorneys' fees and expenses, including awards up to $2,000 for each of two plaintiffs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261103793144) on November 03, 2026, and is solely responsible for the information contained therein.